TFF Pharmaceuticals Management
Management criteria checks 0/4
TFF Pharmaceuticals' CEO is Harlan Weisman, appointed in Dec 2022, has a tenure of 1.33 years. total yearly compensation is $2.08M, comprised of 26.5% salary and 73.5% bonuses, including company stock and options. directly owns 1.29% of the company’s shares, worth $98.08K. The average tenure of the management team and the board of directors is 1.3 years and 2.7 years respectively.
Key information
Harlan Weisman
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 26.5% |
| CEO tenure | 1.3yrs |
| CEO ownership | 1.3% |
| Management average tenure | 1.3yrs |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?
Apr 10
Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?
Sep 27TFF Pharma: The Potential Is Still Very Much Present
Aug 29TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways
Aug 09TFF Pharmaceuticals expands R&D operations with new Austin facility
Jul 14TFF Pharmaceuticals: A Highly Attractive Basket Of Options
May 23We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully
May 17Here's Why We're Not Too Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Situation
Jan 06TFF Pharmaceuticals: Upside Catalysts Starting To Show Up Amid Omicron, But Timidly
Dec 02Companies Like TFF Pharmaceuticals (NASDAQ:TFFP) Are In A Position To Invest In Growth
Sep 16TFF Pharmaceuticals: Cautiously Optimistic
Sep 09TFF Pharma's Platform Is Highly Relevant In The Battle Against The Pandemic
Jul 27TFF Pharmaceuticals: Looking Attractive At These Prices
Jun 03Companies Like TFF Pharmaceuticals (NASDAQ:TFFP) Are In A Position To Invest In Growth
Mar 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$550k | -US$21m |
| Sep 30 2023 | n/a | n/a | -US$24m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | US$594k | US$42k | -US$32m |
| Sep 30 2022 | n/a | n/a | -US$34m |
| Jun 30 2022 | n/a | n/a | -US$36m |
| Mar 31 2022 | n/a | n/a | -US$32m |
| Dec 31 2021 | US$40k | n/a | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$22m |
| Dec 31 2020 | US$241k | n/a | -US$19m |
| Sep 30 2020 | n/a | n/a | -US$41m |
| Jun 30 2020 | n/a | n/a | -US$39m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$216k | n/a | -US$37m |
CEO
Harlan Weisman (71 yo)
1.3yrs
Tenure
US$2,076,038
Compensation
Dr. Harlan F. Weisman M.D. is Operating Partner of CR Group L.P. Dr. Weisman was Senior Advisor of CR Group L.P. from 2012. Dr. Weisman is Clinical Advisor of Protagonist Therapeutics, Inc. Dr. Weisman joi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$2.08m | 1.29% $ 98.1k | |
| CFO, Treasurer & Secretary | 6.3yrs | US$469.07k | 0.057% $ 4.3k | |
| Chief Medical Officer | 1.3yrs | US$865.13k | 0.21% $ 16.3k |
1.3yrs
Average Tenure
59yo
Average Age
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.3yrs | US$2.08m | 1.29% $ 98.1k | |
| Independent Director | 6.3yrs | US$144.53k | 0.089% $ 6.7k | |
| Independent Director | 5.3yrs | US$67.88k | 0.057% $ 4.3k | |
| Chairman of the Scientific Advisory Board and Senior Research & Development Advisor | 1.3yrs | no data | no data | |
| Independent Director | less than a year | US$41.85k | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Independent Director | 2.1yrs | US$70.92k | 0.032% $ 2.4k | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data |
2.7yrs
Average Tenure
51yo
Average Age
Experienced Board: TFFP's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.